Trial record 14 of 24 for:    Pacritinib

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02564536
Recruitment Status : Withdrawn (Lack of funding following full FDA clinical hold)
First Posted : September 30, 2015
Last Update Posted : May 8, 2017
CTI BioPharma
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:

For the first 28 day cycle, all patients will be treated with single agent pacritinib at 200 mg twice daily. The investigators chose this starting dose based on the previous three phase I studies of pacritinib as a single agent which showed that the maximum tolerated dose (MTD) to be 500 mg, and subsequently, the dose of 400 mg daily was recommended for the phase II studies.

Recently, the results of the phase III PERSIST-1 trial comparing pacritinib to best available therapy (BAT) in patients with MF was reported at the 2015 American Society of Clinical Oncology (ASCO) annual meeting. Pacritinib was found to be significantly more effective than BAT at reducing spleen volume at 24 weeks of therapy and improving constitutional symptoms.

Low dose decitabine has demonstrated depletion of DNMT1 in normal hematopoietic stem cells (HSC) without cytotoxicity and subcutaneous (SC) instead of intravenous (IV) administration may avoid high peak levels that can cause apoptosis. Furthermore, the low toxicity associated with low dose decitabine would allow for more frequent (1 to 3 times weekly) administration of the drug which would catch more cells in S-phase via greater exposure time. Based on these findings, a starting dose of decitabine 5 mg/m2 SC twice weekly should be well tolerated and effective in patients with MF and MPN/MDS syndromes when combined with pacritinib 400 mg daily.

Condition or disease Intervention/treatment Phase
Chronic Myelomonocytic Leukemia Juvenile Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Myeloproliferative Neoplasm Myelodysplastic Syndromes Myelofibrosis Drug: Pacritinib Drug: Decitabine Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
Estimated Study Start Date : June 2017
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2020

Arm Intervention/treatment
Experimental: Arm 1: Pacritinib and Decitabine
  • Patients will receive one cycle of single agent pacritinib.
  • Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy.
  • Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced.
  • Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle.
  • Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle.
  • Patients may continue treatment for up to 12 cycles.
Drug: Pacritinib
-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.

Drug: Decitabine
-From commercial stock

Primary Outcome Measures :
  1. Safety of regimen as measured by adverse events [ Time Frame: 30 days after completion of treatment (up to 1 year) ]
    The descriptions and grading for adverse events are found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Secondary Outcome Measures :
  1. Rate of objective response as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) consensus [ Time Frame: End of treatment (up to 48 weeks) ]
    Objective response is defined as CR (complete remission/response) + PR (partial remission/response) + CI (clinical improvement).

  2. Rate of hematologic response [ Time Frame: End of treatment (up to 48 weeks) ]

    -Anemia response

    Anemia response is only applicable for patients with baseline hemoglobin level less than 10g/dL for 8 weeks or more and requires:

    *≥2 g/dL increase in hemoglobin level

    *becoming transfusion-independent (no RBC transfusions in past 1 month)

    -Platelet response

    Platelet response is only applicable for patients with a baseline platelet count of less than 50 x 10^9/L for 8 weeks or more, and requires:

    • 100% increase in platelet count AND
    • An absolute platelet count of at least 50 x 10^9/L

  3. Rate of symptom response as measured by the total symptom score (TSS) [ Time Frame: End of treatment (up to 48 weeks) ]
    A ≥50% reduction in the myeloproliferative neoplasm symptom assessment total symptom score

  4. Rate of spleen response [ Time Frame: End of treatment (up to 48 weeks) ]
    • A baseline splenomegaly that is palpable at 5-10 cm below the left costal margin becomes not palpable OR
    • A baseline splenomegaly that is palpable > 10 cm below the left costal margin decreases by ≥50% OR
    • A baseline splenomegaly that is palpable < 5 cm below the left costal margin is not eligible for spleen response OR
    • MRI or CT shows ≥35% spleen volume reduction

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of:

    • Primary MF or post-PV/ET MF classified as high risk, intermediate-2 risk, or intermediate-1 risk who are unresponsive or unable to receive current therapy which may or may not include ruxolitinib OR
    • MPN/MDS Syndrome (chronic myelomonocytic leukemia [CMML], juvenile myelomonocytic leukemia [JMML], atypical chronic myeloid leukemia [aCML], or MDS/MPN unclassifiable)
  • ECOG 0-3
  • Required laboratory values:

    • Neutrophil count of ≥ 0.5 x 109/L
    • Bone marrow blood blast count < 20%
    • AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
    • Total creatinine < 2.5mg/dL
    • Total bilirubin ≤ 2.0 x ULN
  • Age ≥ 18 years old at enrollment.
  • If female, must be:

    • postmenopausal for at least 1 year before the screening visit OR
    • surgically sterile OR
    • agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatment.
  • Able to swallow pills.
  • If a sexually active heterosexual male, must be agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatment.
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

  • Prior treatment with more than two JAK2 inhibitors or with pacritinib
  • Known positive status for human immunodeficiency virus (HIV)
  • Chronic, active, or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
  • Use of chemotherapy, biologic therapy, radiation therapy, erythropoietin or related erythropoiesis stimulating agents, or investigational therapy within 2 weeks of the first dose of study drug
  • History of allogeneic stem cell transplant or transplant eligible
  • Currently receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
  • Ongoing gastrointestinal medical condition such as Crohn's disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation that could interfere with absorption of oral medication
  • Active bleeding that requires hospitalization during the screening period
  • Cardiovascular disease, including recent history of or currently clinically symptomatic and uncontrolled congestive heart failure, arrhythmia, angina, QTc prolongation or other QTc risk factors, myocardial infarction. Patients with CTCAE grade 2 cardiac arrhythmias may be considered for inclusion if the arrhythmias are stable, asymptomatic, and unlikely to affect patient safety. Patients will e excluded if they have ongoing cardiac dysrhythmias of CTCAE grade ≥ 3, corrected QT interval (QTc) prolongation > 450 ms, or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium < 3.0 mEq/L that is persistent and refractory to correction], or family history of long QT interval syndrome).
  • Other malignancy requiring active treatment at time of study entry
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or serious medical or psychiatric illness/social situations that would limit compliance with study requirements.
  • Life expectancy < 6 months
  • Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14 days of study entry.
  • Receiving treatment with any potent CYP3A4 inhibitors within 7 days of the first dose of study drug
  • Patients with MF who are eligible for enrollment in the pacritinib "PERSIST-2" study at WUSM (NCT02055781) HRPO 201406075.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02564536

Sponsors and Collaborators
Washington University School of Medicine
CTI BioPharma
Principal Investigator: Camille Abboud, M.D. Washington University School of Medicine

Additional Information:
Responsible Party: Washington University School of Medicine Identifier: NCT02564536     History of Changes
Other Study ID Numbers: 201510166
First Posted: September 30, 2015    Key Record Dates
Last Update Posted: May 8, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
Myeloproliferative Disorders
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Pathologic Processes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors